| Bioactivity | Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)[1]. | ||||||||||||
| Target | Kd: 0.54 nM (Factor D) | ||||||||||||
| Invitro | Danicopan (ACH-4471) inhibits the proteolytic activity of purified Factor D against its natural substrate Factor B in complex with C3b, blocking production of Bb fragment in a dose-dependent manner with an IC50 value of 0.015 μM[1].Danicopan (ACH-4471) potently inhibits hemolysis with IC50 values ranging from 0.0040 μM to 0.027 μM (IC90 values from 0.015 μM to 0.11 μM)[1]. | ||||||||||||
| Name | Danicopan | ||||||||||||
| CAS | 1903768-17-1 | ||||||||||||
| Formula | C26H23BrFN7O3 | ||||||||||||
| Molar Mass | 580.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475. |
Danicopan
CAS: 1903768-17-1 F: C26H23BrFN7O3 W: 580.41
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to hu
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.